ICML 2017 | BGB-3111 and ibrutinib for Waldenström’s macroglobulinemia
Christian Buske, MD of University Hospital Ulm, Ulm, Germany talks about the Phase III trial comparing BGB-3111 and ibrutinib in Waldenström’s macroglobulinemia (NCT03053440). The gold standard for treatment in Waldenström’s macroglobulinemia is ibrutinib, which is a BTK inhibitor approved for relapsed patients and in first-line for patients who are not eligible for immunochemotherapy. BGB-3111 is more selective than ibrutinib and therefore thought to be more effective. Preliminary data from a Phase I trial shows that patients treated with BGB-3111 achieve deep remissions and based on this, the Phase III trial was initiated. Prof. Buske explains that we need more data on BGB-3111 before we can assess its impact on clinical practice.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland.
Get great new content delivered to your inboxSign up